Purpose Of Review: To evaluate the current evidence on the use of omadacycline for the treatment of skin and soft tissue infections (SSTIs).
Recent Findings: This narrative review examines the available data on the pharmacology, clinical efficacy, safety profile, and comparative effectiveness of omadacycline in treating SSTIs, with a focus on its potential role in everyday clinical practice.
Summary: Omadacycline is a viable option for outpatient therapy and early discharge in patients with SSTIs, particularly in frail populations and those undergoing chronic polypharmacotherapy. Emerging real-world evidence highlights its potential utility beyond approved indications, particularly for infections caused by multidrug-resistant microorganisms where treatment options are limited. However, further studies are needed to confirm its role in contexts beyond its current approvals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QCO.0000000000001089 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe pneumonia due to concurrent Legionella pneumophila and Acinetobacter baumannii infections: a case report.
BMC Pulm Med
January 2025
Department of Respiratory and Critical Care Medicine, Lishui Hospital of Traditional Chinese Medicine Affiliated to Zhejiang University of Traditional Chinese Medicine, No. 800 Zhongshan Road, Liandu District, Lishui, Zhejiang, 323000, China.
Background: Legionella pneumophila is an uncommon pathogen causing community-acquired atypical pneumonia. Acinetobacter baumannii is a major pathogen responsible for hospital-acquired pneumonia, but it rarely causes serious infections in a community setting. Without prompt and appropriate treatments, infection from either of these two pathogens can cause a high mortality rate.
View Article and Find Full Text PDFThe future approach for the management of acute bacterial skin and skin structure infections.
Curr Opin Infect Dis
January 2025
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.
Purpose Of Review: To discuss the new available options for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and how to implement in the clinical practice innovative approaches for their management.
Recent Findings: The availability of long-acting antibiotics, including dalbavancin and oritavancin, changed the approach to patients with ABSSSI. Direct discharge from the emergency department and early discharge from the hospital should be considered in patients with ABSSSI.
New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).
Antimicrob Agents Chemother
January 2025
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky, USA.
Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant methicillin-resistant (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli.
View Article and Find Full Text PDFIn vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates.
Diagn Microbiol Infect Dis
December 2024
Department of Medical Microbiology, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with limited treatment options due to resistance to multiple antibiotic classes. This study aimed to evaluate the in vitro activity of omadacycline and comparator antibiotics against rapidly growing mycobacteria (RGM) clinical isolates. Minimum inhibitory concentration (MIC) evaluation of RGM clinical isolates was performed by two independent laboratories (EU and Japan).
View Article and Find Full Text PDFDabie bandavirus and Mycoplasma pneumoniae co-infection: a case report.
BMC Infect Dis
January 2025
Jiangxi Medical Center for Critical Public Health Events, Department of Infectious Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No.17 Yongwai Street, Donghu District, Nanchang, 330006, Jiangxi Province, China.
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by Dabie bandavirus (DBV). We report a case of DBV and Mycoplasma pneumoniae (MP) co-infection.
Case Presentation: Here we reported a 57-year-old healthy male who was admitted with the presentations of fever, cough, hemoptysis, and hypotension.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!